• HOT TOPICS
  • LATEST
  • TOP STOCKS
  • SECTORS
    • MINING & RESOURCES
    • BIOTECH & PHARMA
    • TECHNOLOGY
    • OIL, GAS & ENERGY
    • INDUSTRIALS & JUNIORS
  • IPOs
  • TOOLS
    • STOCK SUMMARY
    • ANNOUNCEMENTS
    • VOLUME STOCKS
    • DIRECTOR TRADES
    • SECTOR TRACKER
    • MARKET DATA
    • ULTIMATE GUIDES
  • VIDEOS
  • PODCAST
  • EVENTS
  • SUBSCRIBE
  • English (English)
  • 中文 (Chinese)
Search
  • EN
  • |
  • 中文
Small Caps ASX stock market news Australia shares Small Caps
Small Caps ASX stock market news Australia shares Small Caps ASX stock market news Australia shares
  • HOT TOPICS
  • LATEST
  • TOP STOCKS
  • SECTORS
    • MINING & RESOURCES
    • BIOTECH & PHARMA
    • TECHNOLOGY
    • OIL, GAS & ENERGY
    • INDUSTRIALS & JUNIORS
  • IPOs
  • TOOLS
    • STOCK SUMMARY
    • ANNOUNCEMENTS
    • VOLUME STOCKS
    • DIRECTOR TRADES
    • SECTOR TRACKER
    • MARKET DATA
    • ULTIMATE GUIDES
  • VIDEOS
  • PODCAST
  • EVENTS
  • SUBSCRIBE
  • English (English)
  • 中文 (Chinese)

BIOTECH & PHARMA

  • BIOTECH & PHARMA
  • HOT TOPICS
  • INDUSTRIALS & JUNIORS
  • MINING & RESOURCES
  • OIL, GAS & ENERGY
  • TECHNOLOGY
  • UPCOMING FLOATS

    Biotech and pharma stocks listed on the ASX.

    Incannex Healthcare ASX IHL world’s largest portfolio patented medicinal cannabis drug formulations APIRx Pharmaceuticals

    Incannex Healthcare officially owns world’s largest portfolio of patented medicinal cannabis drug formulations

    August 5, 2022
    Incannex ASX IHL Curia manufacture neuroprotective cannabinoid combination drug IHL-216A concussion traumatic brain injury TBI

    Incannex to scale up manufacture of neuroprotective cannabinoid combination drug IHL-216A

    August 2, 2022
    InhaleRx ASX IRX inhaled cannabinoid based formulations panic disorder CRPS complex regional pain syndrome

    InhaleRx fast-tracks development of inhaled cannabinoid-based formulations for panic disorder and CRPS

    August 1, 2022
    PharmAust ASX PAA markets monepantel MPL trial success

    PharmAust opens door to billion-dollar markets, following MPL trial successes

    August 1, 2022
    Incannex Healthcare ASX IHL cannabinoid psychedelic medicine programs FDA cannabis psilocybin

    Incannex Healthcare progresses cannabinoid and psychedelic medicine programs

    July 27, 2022
    Incannex Healthcare ASX IHL phase 1 clinical trial IHL-675A inflammatory lung conditions bowel disease rheumatoid arthritis

    Incannex Healthcare to begin phase 1 clinical trial for IHL-675A following ethics approval

    July 21, 2022
    PharmAust PAA ASX monepantel trials motor neurone disease canine cancer

    PharmAust focuses in on monepantel trials for motor neurone disease and canine cancer

    July 20, 2022
    Wellnex Life ASX WNX OneLife Botanicals joint venture medicinal cannabis hemp products

    Wellnex Life teams up with OneLife Botanicals to penetrate Australia’s medicinal cannabis market

    July 18, 2022
    Kazia Therapeutics KZA ASX Scientific Advisory Board brain cancer

    ‘World-leading’ brain cancer experts headline Kazia Therapeutics’ new scientific advisory board

    July 12, 2022
    Argenica Therapeutics ASX AGN reduce brain tissue death after stroke peer reviewed published study safety ARG-007

    Argenica Therapeutics reports positive findings from peer-reviewed study of stroke drug ARG-007

    July 8, 2022
    Botanix Pharmaceuticals ASX BOT dermatology New Drug Approval NDA Sofpironium Bromide gel

    Botanix Pharmaceuticals prepares new drug application for novel gel to treat excessive underarm sweating

    July 7, 2022
    Kazia Therapeutics ASX KZA US FDA rare drug designation paxalisib childhood brain cancer atypical rhabdoid teratoid tumour

    Kazia Therapeutics awarded US FDA rare drug designation for paxalisib in childhood brain cancer

    July 7, 2022
    Invex Therapeutics ASX IXC June Quarterly 2022

    Invex Therapeutics in strong position to launch Presendin trials

    July 6, 2022
    Invex Therapeutics ASX IXC approved Presendin EVOLVE phase three Australia Human Research Ethics Committee HREC Clinical Trial Notification CTN scheme Therapeutics Goods Administration TGA

    Invex Therapeutics approved to start Presendin phase three clinical trial in Australia

    July 4, 2022
    Kazia Therapeutics ASX KZA paxalisib EVT801 drug development clinical study

    Kazia Therapeutics reports good half-year progress despite market challenges

    June 30, 2022
    Invex Therapeutics ASX IXC MHRA clinical trial Medicines and Healthcare products Regulatory Agency IIH EVOLVE Phase III clinical trial United Kingdom UK Idiopathic Intracranial Hypertension

    Invex Therapeutics gains UK regulatory approval for clinical trial of Presendin to treat idiopathic intracranial hypertension

    June 29, 2022
    Kazia Therapeutics ASX KZA US FDA orphan drug designation paxalisib childhood brain cancer

    Kazia Therapeutics collars US FDA orphan drug designation for paxalisib in a highly aggressive childhood brain cancer

    June 17, 2022
    Greenlab Helius Therapeutics medicinal cannabis treatments New Zealand NZ

    Greenlab joins forces with Helius Therapeutics to develop targeted medicinal cannabis treatments

    June 15, 2022
    Kazia Therapeutics ASX KZA brain tumour positive data paxalisib childhood cancers

    Kazia Therapeutics presents ‘positive data’ on paxalisib in childhood brain cancers

    June 14, 2022
    Prescient Therapeutics ASX PTX high performance cell therapy technology CellPryme-M

    Prescient Therapeutics unveils high performance cell therapy technology CellPryme-M

    June 8, 2022
    Kazia Therapeutics ASX KZA paxalisib study secondary brain tumours breast cancer

    Kazia Therapeutics expands paxalisib study to include secondary brain tumours from breast cancer

    June 8, 2022
    Load more
    Small Caps ASX stock market news Australia shares
    Small Caps is Australia's #1 site for market news & information on ASX listed small cap companies.

    Small Caps and affiliated companies accept no responsibility for any claim, loss or damage as a result of information provided or its accuracy. The information provided on this site is general in nature, not financial product advice, see a financial expert before making any investment decision. Your personal objectives, financial situation or needs have not been taken into consideration. There may be a conflict of interest present with commercial arrangements with companies and/or stock held. Small Caps or an associate may receive a commission for funds raised.
    • English
    • 中文 (Chinese)
    • ADVERTISE
    • ABOUT
    • TERMS
    • PRIVACY
    • NEWSLETTER
    • CONTACT US
    Copyright 2022 Small Caps. All rights reserved.